The salient features of our manufacturing facility in the United States of America are:

	US FDA approved, cGMP-compliant manufacturing facility in Maryland, USA.
	Spread over an area of around 3,500 sq mtr,
	Annual production capacity: 1.6 to 1.8 bn tabs and 520 mn caps per annum on double-shift basis.
	Dedicated production line for steroidal dosage forms
	Dedicated team of 110 techno-commercials

 The salient features of our manufacturing facility in India are:

	Located in Roorkee, Uttarakhand (4 hrs. drive from Delhi)
	Set-up in July 2007
	USFDA UKMHRA approved
	Annual production capacity of 1.2 bn tablets and 330 mn capsules
	Will cater to supplies of finished dosage form to US, Europe and some select emerging markets.
	Production capabilities span across various IR, NDDS and taste masked solid orals by: wet and dry granulation, direct compression, encapsulation, spheronisation and extrusion as well as packaging – both blisters and bottle packs.
	Dedicated team of more than 120 people.